Am J Transplant, Volume 18, Suppl 3 Archives - Page 27 of 211 - ATC Abstracts

2018 American Transplant Congress
Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma Treated with Neoadjuvant Therapy: A Pilot Cohort Study
K. Lunsford,¹ M. Javle,² K. Heyne,¹ R. Shroff,² R. Hassan Ali,² C. Mobley,¹ D. Victor,¹ A. Kaseb,² T. Aloia,² C. Conrad,² X. Li,¹ H. Monsour,¹ A. Gaber,¹ J-.N. Vauthey,² R. Ghobrial.¹
¹Houston Methodist Hospital, Houston, TX; ²MD Anderson Cancer Center, Houston, TX.
INTRODUCTIONIntrahepatic cholangiocarcinoma (iCCA) is a well-recognized contraindication for liver transplantation (LT). Recent reports indicate favorable LT outcomes for early iCCA (<2cm), but, poor survival persists…
2018 American Transplant Congress
High Prevalence of Hypertension and Alterations in Rhythmicity in Recipients of Pediatric Transplants
N. Memaran,¹ M. Kirchner,² R. Blöte,¹ B. Maecker-Kolhoff,³ I. Goldschmidt,¹ C. Müller,⁴ J. Epping,⁵ R. Sugianto,¹ B. Borchert,¹ B. Schmidt,⁶ E. Wühl,⁷ A. Melk.¹
¹Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Med. School, Hanover, Germany; ²Department of Medical Biometry, University of Heidelberg, Heidelberg, Germany; ³Department of Pediatric Hematology and Oncology, Hannover Med. School, Hanover, Germany; ⁴Department of Pediatric Pulmonology, Allergology, and Neonatology, Hannover Med. School, Hanover, Germany; ⁵Department of Medical Sociology, Hannover Med. School, Hanover, Germany; ⁶Department of Nephrology and Hypertension, Hannover Med. School, Hanover, Germany; ⁷Division of Pediatric Nephrology, University Children's Hospital, Heidelberg, Germany.
Hypertension (HTN) is a major issue after transplantation (Tx). Ambulatory blood pressure (BP) monitoring (ABPM) permits the diagnosis of masked HTN and nocturnal HTN. Fourier…
2018 American Transplant Congress
Comparative Cost Analysis of ABO-Incompatible Living Kidney Transplantation
Y. Kakuta,¹ M. Okumi,¹ K. Unagami,² M. Furusawa,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical School, Tokyo, Japan; ²Nephrology, Tokyo Women's Medical School, Tokyo, Japan.
BackgroundABO-incompatible living kidney transplantation (ABO-I) has been accepted as a valid alternative therapy for patients with end-stage kidney disease. The number of ABO-I has been…
2018 American Transplant Congress
Sustained Improvement in Patient Reported Outcomes 10 Years after Liver Transplantation by Protocol Longitudinal Assessment of Health Related Quality of Life
S. Elwir,¹ A. Warren,¹ G. Saracino,¹ S. Asrani,¹ T. Elliott,² G. Klintmalm.¹
¹Baylor University Medical Center, Dallas, TX; ²Department of Educational Psychology, Texas A&M University, College Station, TX.
Purpose: Data on patient (pt) reported outcomes, especially beyond the first year after liver transplantation (LT) are scarce. We examined changes in health related quality…
2018 American Transplant Congress
Patient-Centered Outcomes after Liver Transplantation: A Qualitative Study
G. Lee, J. Obayemi, E. Rubin.
Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA; Medicine, Massachusetts General Hospital, Boston, MA.
Introduction: Outcomes after liver transplantation are most commonly reported by medical professionals as rates of graft failure, episodes of acute rejection, length of hospital stay,…
2018 American Transplant Congress
Survival, Cancer and PTLD Diagnosis after Late EBV Infection in Adult Kidney Transplantation
M. Morton,¹ G. Scullin,² K. Daga,² P. Klapper,² P. Vallely,² M. Picton.¹
¹Department of Renal Medicine, Manchester Royal Infirmary, Manchester, United Kingdom; ²Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.
Introduction: While EBV seronegative recipients have a high risk of early PTLD knowledge is lacking regarding the implications of EBV DNAemia in stable patients in…
2018 American Transplant Congress
Predicting Outcomes of Rat Vascularized Composite Allotransplants through Quantitative Measurement of Chimerism with PCR-Amplified Short Tandem Repeat
H. Cheng,¹ X. Huang,² C-.F. Lin,¹ N. AL Deek,² L. Shih,² C-.H. Lin,^1,2 F-.C. Wei.^1,2,3
¹Center for Vascularized Composite Allotransplantation, Linkou Chang Gung Memorial Hospital, Gueishan, Taoyuan, Taiwan; ²Department of Plastic and Reconstructive Surgery, Linkou Chang Gung Memorial Hospital, Gueishan, Taoyuan, Taiwan; ³College of Medicine, Chang Gung University, Gueishan, Taoyuan, Taiwan.
Background: Chimerism, defined as coexistence of donor and recipient cells, has been associated with induction and maintenance of tolerance to allotransplants. Although most studies have…
2018 American Transplant Congress
The Novel Polymer Pro-Drug APP-103 Reduces I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model
K. Minami,^1,3 H. Uehara,^1,3 A. Elkhal,^1,3 A. Weins,³ S. Bae,^2,3 J. Reder,⁴ B. Houser,⁴ P. Kang,^2,3 S. Tullius.^1,3
¹Transplant Surgery Division, Department of Surgery, Brigham and Women's Hospital, Boston, MA; ²Beth Israel Deaconess Medical Center, Boston, MA; ³Harvard Medical School, Boston, MA; ⁴Celdara Medical, LLC, Lebanon, NH.
Purpose: Ischemia-reperfusion injury (IRI) is the strongest non-HLA factor that augments allogenicity of transplanted organs. Damage subsequent to IRI is critically linked to an abundance…
2018 American Transplant Congress
Lower Incidence of De Novo Donor-Specific Antibodies against HLA-DR in ABO-Incompatible Renal Transplantation
M. Okada,¹ K. Futamura,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ Y. Watarai,¹ K. Iwasaki,² T. Kobayashi.²
¹Department of Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Department of Transplant Surgery, Aichi Medical University, Nagakute, Japan.
IntroductionDe novo DSA-induced chronic antibody-mediated rejection (AMR) is one of major obstacles to long term graft survival. We have reported that anti-A/B antibody binding could…
2018 American Transplant Congress
Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts
M. Everly,¹ V. Jucaud,¹ M. Roberts,² H. Gebel,³ R. Bray.³
¹Terasaki Research Institute, Los Angeles, CA; ²Immunology Biomarker Group, Bristol-Myers Squibb, Princeton, NJ; ³Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
The use of belatacept over cyclosporine is associated with lower rates of DSA development in adult kidney transplantation. However, the effect of belatacept on the…